ResearchMoz

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

GBI Research
Published Date » 2014-03-07
No. Of Pages » 109
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘NSCLC Therapeutics in APAC Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool’, which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8...
Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 12
2.4 Co-morbidities and Complications 12
2.5 Diagnosis 13
2.5.1 Physical Examination 13
2.5.2 Sputum Cytology 13
2.5.3 Imaging Tests 13
2.5.4 Biopsy 14
2.6 Classification 15
2.6.1 Adenocarcinoma 15
2.6.2 Squamous Cell Carcinoma 15
2.6.3 Large Cell Carcinoma 15
2.7 Epidemiology 15
2.8 Prognosis and Disease Staging 16
2.8.1 Staging 16
2.9 Treatment Options 18
2.9.1 Surgery and Radiation Therapy 18
2.9.2 Pharmacological 18
2.9.3 Treatment Algorithms and Prescribing Habits 20

3 Marketed Products 23
3.1 Therapeutic Landscape 24
3.1.1 Alimta (pemetrexed disodium) – Eli Lilly and Company 24
3.1.2 Abraxane (nab-paclitaxel) – Celgene 26
3.1.3 Iressa (gefitinib) – AstraZeneca 28
3.1.4 Tarceva (erlotinib hydrochloride) – F. Hoffmann-La Roche 29
3.1.5 Xalkori (crizotinib) – Pfizer 31
3.1.6 Avastin (bevacizumab) – F. Hoffmann-La Roche 32
3.1.7 Gilotrif (afatinib) – Boehringer Ingelheim 34
3.2 Comparative Efficacy and Safety 34

4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 39
4.3 Pipeline Analysis by Mechanism of Action 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Patient Enrollment and Clinical Trial Size 46
4.4.3 Duration 48
4.5 Promising Drug Candidates in the Pipeline 50
4.5.1 Ramucirumab (IMC-1121B) – Eli Lilly and Company 50
4.5.2 Necitumumab (IMC-11F8) – Eli Lilly and Company 50
4.5.3 Onartuzumab (MetMab) – F. Hoffmann-La Roche 51
4.5.4 Ganetespib (STA-9090) – Synta 52
4.5.5 Nintedanib (BIBF1120) – Boehringer Ingelheim 52
4.5.6 Dacomitinib (PF-00299804) – Pfizer 53
4.5.7 LDK378 – Novartis 54
4.5.8 Yervoy (ipilimumab) – Bristol-Myers Squibb 54
4.5.9 Nivolumab (BMS-936558/ONO-4538) – Bristol Myers Squibb 55

5 Market Forecast to 2019 56
5.1 Geographical Markets 56
5.1.1 APAC Market 56
5.1.2 India 57
5.1.3 Australia 60
5.1.4 China 62
5.1.5 Japan 64
5.2 Drivers and Barriers for the Disease Market 66
5.2.1 Drivers 66
5.2.2 Barriers 66

6 Deals and Strategic Consolidations 68
6.1 Major Co-development Deals 69
6.1.1 OxOnc Enters Co-development Agreement with Pfizer for Crizotinib 70
6.1.2 SFJ Pharma Enters Co-development Agreement with Pfizer for Dacomitinib 70
6.1.3 Merck Enters Co-development Agreement with Endocyte for Cancer Drug 71
6.1.4 Roche Enters Co-development Agreement with Clovis 71
6.1.5 Abbott Laboratories Enters Co-development Agreement with GlaxoSmithKline 71
6.2 Major Licensing Deals 71
6.2.1 Chugai Enters Licensing Agreement with Roche for Onartuzumab and Lebrikizumab 72
6.2.2 Azaya Enters Licensing Agreement with CANbridge Life Sciences for ATI-1123 73
6.2.3 Merck Expands Licensing Agreement with Biomira 73
6.2.4 Clovis Enters Licensing Agreement with Avila Therapeutics 73

7 Appendix 74
7.1 All Pipeline Drugs by Phase 74
7.1.1 Discovery 74
7.1.2 Preclinical 75
7.1.3 IND-filed 78
7.1.4 Phase I 78
7.1.5 Phase II 82
7.1.6 Phase III 86
7.1.7 Undisclosed 89
7.2 Market Forecasts to 2019 97
7.2.1 APAC 97
7.2.2 India 98
7.2.3 Australia 98
7.2.4 China 98
7.2.5 Japan 99
7.3 Market Definitions 99
7.4 Abbreviations 99
7.5 Bibliography 102
7.6 Research Methodology 105
7.6.1 Coverage 105
7.6.2 Secondary Research 106
7.6.3 Primary Research 106
7.6.4 Therapeutic Landscape 106
7.6.5 Geographical Landscape 108
7.6.6 Pipeline Analysis 109
7.7 Expert Panel Validation 109
7.8 Contact Us 109
7.9 Disclaimer 109

List of Tables

Table 1: Non-Small Cell Lung Cancer Market, Common Symptoms of Non-Small Cell Lung Cancer 11
Table 2: Non-Small Cell Lung Cancer Market, Risk Factors of Non-Small Cell Lung Cancer Market 12
Table 3: Non-Small Cell Lung Cancer Market, American Joint Committee on Cancer’s Tumor Node Metastasis Staging System, 2010 17
Table 4: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Discovery), 2013 74
Table 5: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 75
Table 6: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (IND-filed), 2013 78
Table 7: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase I), 2013 78
Table 8: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase II), 2013 82
Table 9: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Phase III), 2013 86
Table 10: Non-Small Cell Lung Cancer Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 89
Table 11: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Forecast, 2012–2019 97
Table 12: Non-Small Cell Lung Cancer Market, India, Market Forecast, 2012–2019 98
Table 13: Non-Small Cell Lung Cancer Market, Australia, Market Forecast, 2012–2019 98
Table 14: Non-Small Cell Lung Cancer Market, China, Market Forecast, 2012–2019 98
Table 15: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2012–2019 99

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Asia-Pacific, Distribution of Prevalence Population, 2012–2019 16
Figure 2: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 20
Figure 3: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Early and Advanced Localized Tumors Stages IIIA and IIIB, 2013 21
Figure 4: Non-Small Cell Lung Cancer Market, Treatment Algorithm for Advanced Metastatic Tumors, 2013 22
Figure 5: Non-Small Cell Lung Cancer Market, Global, Annual Sales, 2012 24
Figure 6: Non-Small Cell Lung Cancer Market, Global, Alimta (pemetrexed disodium) Annual Sales ($bn), 2004–2012 25
Figure 7: Non-Small Cell Lung Cancer Market, Global, Abraxane (nab-paclitaxel) Annual Sales ($m), 2009–2012 27
Figure 8: Non-Small Cell Lung Cancer Market, Global, Iressa (gefitinib) Annual Sales ($m), 2005–2012 28
Figure 9: Non-Small Cell Lung Cancer Market, Global, Tarceva (erlotinib) Annual Sales ($bn), 2006–2012 30
Figure 10: Non-Small Cell Lung Cancer Market, Global, Xalkori (crizotinib) Annual Sales ($m), 2012–2013 31
Figure 11: Non-Small Cell Lung Cancer Market, Global, Avastin (bevacizumab) Annual Sales ($bn), 2006–2012 33
Figure 12: Non-Small Cell Lung Cancer Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 35
Figure 13: Non-Small Cell Lung Cancer Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013 38
Figure 14: Non-Small Cell Lung Cancer Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 40
Figure 15: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, 2013 42
Figure 16: Non-Small Cell Lung Cancer Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2013 43
Figure 17: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Failure Rate (%), 2013 45
Figure 18: Non-Small Cell Lung Cancer Market, Global, Clinical Trial Size (Participants), 2013 47
Figure 19: Non-Small Cell Lung Cancer Market, Global, Pipeline Clinical Trial Duration (months), 2013 49
Figure 20: Non-Small Cell Lung Cancer Market, Asia-Pacific, Market Size, 2012–2019 57
Figure 21: Non-Small Cell Lung Cancer Market, India, Market Size, 2012–2019 59
Figure 22: Non-Small Cell Lung Cancer Market, Australia, Market Size, 2012–2019 61
Figure 23: Non-Small Cell Lung Cancer Market, China, Market Size, 2012–2019 63
Figure 24: Non-Small Cell Lung Cancer Market, Japan, Market Size, 2012–2019 65
Figure 25: Non-Small Cell Lung Cancer Market, Global Deals by Value, Year and Stage of Development, 2006–2013 68
Figure 26: Non-Small Cell Lung Cancer Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013 69
Figure 27: Non-Small Cell Lung Cancer Market, Global, Co-development Deals by Geography, 2006–2013 70
Figure 28: Non-Small Cell Lung Cancer Market, Global, Licensing Deals by Geography, 2006–2013 72
Figure 29: GBI Research Market Forecasting Model (Example) 108

Upcoming Reports:

Novolac Resins Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Novolac resins are among the most dominant types of phenolic resins. Novlac resins are produced by the reaction of phenol and formaldehyde in the presence of an acidic catalyst. Phenols employed in the production process typically include resorcinol, cresol or bio-based products such as nutshell of cashew. Hexamine is commonly used as a source of formaldehyde in the production process.  Novolac resins possess several characteristics such as high thermal stability, high strength, light weight and can be molded easily. Their physical properties make novolac resin suitable for...
Semi-Submersible Rigs market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast, 2014 - 2020
By - Transparency Market Research
Semi submersible rigs are specialized marine vessels and are specifically used for the offshore oil and gas drilling market. The growth of the offshore drilling industry in the future is likely to facilitate the market demand for semi submersible rigs during the forecasted period. Fixed structures are not feasible for carrying out offshore drilling activities which is why these semi submersible rigs are gradually coming into demand. The semi submersible rigs comprise of a deck supported by pillars, which are further connected to pontoons. The pontoons generally go entirely...
Bio-based & Low-VOC Paints Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
VOCs (volatile organic compounds) are substances such as formaldehyde which are used in paints to allow them to dry faster. These are highly toxic to humans and high levels of VOC in paints results in the release of toxic VOC fumes for a long period of time. Low VOC paints use water as a solvent instead of petroleum-based materials. Bio-based paints use raw materials derived from natural sources such as plants and natural minerals which include plant oils, plant dyes, essential oils, clay, beeswax, mineral dyes, and talcum among others. Bio-based and low-VOC paints embed low VOC...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...